Macroplastique Gets FDA Go-Ahead Following Warning Letter Resolution
This article was originally published in The Gray Sheet
Executive Summary
Uroplasty's Macroplastique urinary incontinence bulking agent secured PMA approval Oct. 30 and will launch in the U.S. early in 2007 now that the firm has resolved an FDA warning letter
You may also be interested in...
New Bulking Agent To Be Marketed By “Major” Urology Firm – BioForm
BioForm Medical is completing a deal with a "major urology player" to market and distribute its new female stress urinary incontinence (SUI) therapy
Regulatory News In Brief
CoA guidance: CDRH draft guidance on condition-of-approval study reports clears FDA's Office of Chief Counsel vetting process and should be released shortly, according to an Office of Surveillance and Biometrics staffer. Responsibility for tracking and reviewing CoA studies was transferred to OSB from the Office of Device Evaluation in January (1"The Gray Sheet, April 11, 2005, p. 8)...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.